466 results about "Lipid lowering" patented technology

The disclosure provides methods of reducing the risk of a major adverse cardiovascular event (MACE) in a subject having previously experienced acute coronary syndrome (ACS) and for reducing risk of a MACE in a patient who is diagnosed with coronary artery disease and has blood high-sensitivity C- reactive (hs-CRP) of >2.0 mg / L. The methods include administering to the subject an anti-oxLDL antibody. The anti-oxLDL antibody may be administered to the subject alone or in combination with one or more additional therapeutic agents, such as one or more lipid lowering agents.

The invention relates to the technical field of microorganisms, in particular to a plant lactobacillus BD7807 and application thereof in treating lipid metabolism disorder, and particularly discloses a plant lactobacillus BD7807 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.33630. The invention further discloses a preparation method of the plant lactobacillus BD7807. The plant lactobacillus BD7807 has obvious lipid-lowering, anti-oxidation and adhesion capabilities, is bacteriostatic, has no multiple drug resistance, can play a role in lowering lipid without damaging other organs, and can be widely used for preventing and treating related symptoms caused by lipid metabolism disorder.

The invention discloses hawthorn leaf pectic polysaccharide with lipid-lowering activity and a preparation method and application thereof, and belongs to a preparation method of plant polysaccharide, the preparation method comprises the following steps: refluxing hawthorn leaves with ethanol, discarding monosaccharide and small molecule compounds, refluxing with hot water to extract medicinal materials, removing protein through an enzymolysis method and a Sevage reagent method, decolorizing with polyamide resin, and drying to obtain the hawthorn leaf pectic polysaccharide with lipid-lowering activity. The crude polysaccharide is separated through DEAE-52 column chromatography, and finally, the crude polysaccharide is further purified through Sephadex G-100, so that the uniform purified polysaccharide is obtained. Tests on pancreatic lipase inhibition, taurocholate binding capacity and glycocholate binding rate show that the compound has remarkable lipid-lowering activity and is expected to become a potential natural lipid-lowering preparation.

The present application relates to the technical field of oat bran deep processing, and particularly relates to an oat active polypeptide with GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity, and a preparation method and application thereof.The present application is prepared by adding alkaline protease and ficin for double-enzyme step-by-step hydrolysis after homogenate, enzymolysis and alkali extraction and acid precipitation pretreatment, and then filtering, ultrafiltration desalination and drying, so that the oat active polypeptide with GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity is obtained.The present application is simple to operate, low in equipment requirement, and suitable for industrial large-scale production.The prepared oat active polypeptide has GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity, has a significant inhibitory effect on pancreatic lipase and alpha-glucosidase, has an obvious GLP-1 secretion promotion effect, and has a significant blood sugar reduction and lipid reduction effect.

The invention discloses pancreatic lipase immobilized composite nano magnetic beads, a preparation method and application, ferroferric oxide is adopted as a magnetic core, dopamine-mediated growth is performed to form a core-shell structure, then the periphery of the core-shell structure is wrapped with a metal organic framework to form the composite nano magnetic beads, and pancreatic lipase is immobilized by using the composite nano magnetic beads as an adsorption carrier. The enzyme loading amount, the repeated utilization rate and the storage stability of the ferroferric oxide nano-particles are remarkably improved, the enzyme immobilization efficiency and the enzyme activity are improved, and meanwhile, the prepared pancreatic lipase immobilized composite nano-magnetic beads have excellent stability and biocompatibility, are green and pollution-free and can be repeatedly used; the composite nano magnetic beads are synthesized by adopting a solvothermal method, the product is easy to separate, the synthesis process is simple, the enzyme immobilization efficiency can be regulated and controlled by regulating and controlling the synthesis process, the structure of an active ligand can be screened and analyzed from natural products with numerous and jumbled components, and the active ligand has a certain lipid-lowering potential and can be used for preparing the nano magnetic beads. The compound can be used as a potential lead compound of lipid-lowering drugs.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

The application discloses a Weizmannia coagulans with fat-reducing and weight-reducing functions, and belongs to the technical field of microorganisms. The Weizmannia coagulans screened by the application can inhibit the content and activity of fat synthesis enzyme on the basis of reducing blood fat and weight, can relieve liver damage caused by high-fat diet, has excellent acid tolerance, bile salt tolerance and high fat hydrolysis capacity, and is a multifunctional Weizmannia coagulans, and has a wide application prospect in the preparation of fat-reducing, weight-reducing and weight-losing products.

The invention discloses emblic leafflower fruit polysaccharide with sugar-controlling and lipid-lowering activity as well as a preparation method and application of the emblic leafflower fruit polysaccharide. The polysaccharide is prepared by taking fresh phyllanthus emblica pulp as a raw material through hot water extraction, yeast fermentation, desorption after XAD-16 macroporous resin adsorption, alcohol precipitation, ultrafiltration and DEAE-52 cellulose column purification. The low-molecular-weight gulcomannan is separated from phyllanthus emblica for the first time, and monosaccharide composition of the gulcomannan mainly comprises glucose, mannose and galactose and contains trace rhamnose and xylose. The polysaccharide has sugar-controlling and lipid-lowering active action targets in the whole digestive tract (the upper digestive tract: glycolipid digestion and absorption enzymes alpha-amylase, alpha-glucosidase and pancreatic lipase inhibitory activity, starch hydrolysis delay, bile acid adsorption capacity and cholesterol micelle dissolution inhibition capacity; in the lower digestive tract, the multiplication promoting capacity of glycolipid metabolism-related probiotics) shows extremely high biological activity, and can be applied to food and health care products.

The invention discloses a composition for assisting in reducing blood sugar and blood fat as well as a preparation method and application thereof, and relates to the technical field of functional compositions. The composition comprises highland barley powder and modified inulin, the preparation method of the highland barley powder comprises the following steps: soaking highland barley grains in a weakly alkaline aqueous solution, and sequentially carrying out first pulse microwave treatment, enzyme deactivation treatment and segmented baking treatment; the segmented baking treatment comprises first-stage baking treatment and second-stage intermittent infrared irradiation treatment; the temperature of the first-stage baking treatment is 40-60 DEG C; the temperature of the second-stage intermittent infrared irradiation treatment is 60-80 DEG C, and the emission wavelength is 2.5-4 microns; the preparation method of the modified inulin comprises the following steps: performing acidolysis treatment on inulin in a weakly acidic aqueous solution, and then drying. The highland barley powder and the modified inulin in the embodiment can synergistically improve glycometabolism and lipid metabolism, effectively reduce the body weight, blood sugar, blood fat and the like under high-glucose and / or high-fat diet, and protect and repair the pancreas islet function.

The invention discloses fermentation liquor of a traditional Chinese medicine preparation, a preparation method of the fermentation liquor and application of the fermentation liquor in the aspects of losing weight, lowering lipid and / or relieving liver injury. The traditional Chinese medicine preparation is prepared from the following components in parts by weight: 3 to 6 parts of mulberries, 3 to 6 parts of raspberries, 3 to 6 parts of fructus corni, 12 to 20 parts of fructus lycii, 15 to 25 parts of rhizoma polygonati, 15 to 25 parts of fructus crataegi and 2 to 5 parts of semen cassiae. The traditional Chinese medicine preparation is prepared by extracting, sterilizing, cooling, inoculating a leavening agent and fermenting. The mulberry, the raspberry and the dogwood which are medicinal and edible materials are used for replacing fleece-flower root, the original formula of the lipid-lowering drug is combined, the fermentation liquor prepared after fermentation can effectively retain the obesity adjusting effect of the classic formula of the lipid-lowering drug, meanwhile, the biological activity of the lipid-lowering drug is remarkably improved through the optimized compatibility and the probiotic fermentation technology, and the lipid-lowering drug has a good application prospect. A safe and efficient innovative scheme is provided for functional food to intervene in obesity / overweight.

The present application relates to the technical field of traditional Chinese medicine, in particular to a kind of slimming traditional Chinese medicine composition and preparation method thereof.The present application uses the raw materials such as Buzha Leaf, hawthorn, lotus leaf, immature fruit of Chinese citron, magnolia officinalis, raphanus sativus, dried orange peel, pellitory, alisma orientalis and cassia obtusifolia, after decoction, lactic acid lactobacillus lactis CICC 6242 and royi mucous lactobacillus CICC 6121 are fermented with 0.4-0.8:1 ratio, then combined enzymolysis is carried out using ginger protease and snail protease, and then 15-25wt% ethanol is used for extraction, and the composition is endowed with excellent lipid-lowering and weight loss effect.

The invention relates to the technical field of polypeptide drugs for metabolic diseases, in particular to a glucagon-like peptide (GLP-1), a glucose-dependent insulinotropic polypeptide (GIP) and a glucagon (GCG) triple receptor agonist (protein). According to the triple receptor agonist protein provided by the technical scheme, weight reduction is achieved, meanwhile, lower side effects are shown, and drug compliance is enhanced. The triple receptor stimulant researched and developed by the technical scheme can be applied to preparation of medicines with the effects of losing weight, reducing lipid or reducing blood sugar, solves the technical problem that the existing GLP-1, GIP and GCG triple receptor stimulants are difficult to reduce side effects while reducing body weight, and breaks through the weight loss mode that the traditional medicines depend on appetite suppression; due to the unique action mechanism and good safety, a safer and more effective treatment scheme is provided for patients, and the medicine has wide market prospects and social benefits.

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

The invention is applied to the technical field of health-care products, and discloses a sea-buckthorn soft capsule, which comprises a capsule shell and a content, the capsule shell is composed of gelatin, water, glycerin and an auxiliary material, the auxiliary material is a preservative or a plasticizer, the content is composed of one of seabuckthorn seed oil or fruit oil, seabuckthorn powder and an auxiliary material, the auxiliary material is one of a suspending aid and an antioxidant or a mixture of the suspending aid and the antioxidant, the seabuckthorn powder is rich in flavone, and the auxiliary material is a mixture of the suspending aid and the antioxidant. The soft capsule has the effects of lowering lipid, softening blood vessels and preventing vascular diseases. According to the hippophae rhamnoides soft capsule, a product capsule shell is prepared from gelatin, water and glycerin according to a specific proportion, it can be guaranteed that the capsule shell has proper hardness and elasticity and is convenient to process and store, hippophae rhamnoides seed (fruit) oil and hippophae rhamnoides powder in the content are matched according to a reasonable proportion, the hippophae rhamnoides powder is rich in flavone, and the hippophae rhamnoides powder and the hippophae rhamnoides seed (fruit) oil act the effects of lowering lipid, softening blood vessels and preventing vascular diseases can be better exerted.

The invention discloses a lactobacillus rhamnosus HX-4F3 strain and application thereof, and belongs to the technical field of biology. The lactobacillus rhamnosus HX-4F3 disclosed by the invention is preserved in the China Center for Type Culture Collection, and the preservation number of the lactobacillus rhamnosus HX-4F3 is CCTCC (China Center for Type Culture Collection) NO: M 20251454. The invention discloses an application of a strain HX-4F3 in preparation of drugs or food for lowering lipid or / and blood sugar. The invention also discloses application of the compound in preparation of functional food or / and medicines for preventing or / and treating metabolic diseases. The invention also discloses a composition for lowering lipid or / and blood sugar, which comprises a live bacterium of the strain HX-4F3 or freeze-dried powder, a spore preparation, a metabolic supernatant or an inactivated bacterium of the strain HX-4F3, and a pharmaceutically or food acceptable carrier. According to the lactobacillus rhamnosus HX-4F3 provided by the invention, the glucose and lipid metabolism disorder can be remarkably improved through a multiple synergistic mechanism, and the glucose and lipid metabolism disorder can be remarkably improved through the lactobacillus rhamnosus HX-4F3.

The invention relates to a preparation method and application of a medicine-food homologous compound with weight-losing and lipid-lowering effects. According to the present invention, the weight of the obese mouse can be reduced by 23.23% at most, the serum total cholesterol is reduced, the leptin secretion is reduced, AST (aspartate transaminase) and ALT (alanine transaminase) have no significant difference compared to the model mouse, the volume of epididymal fat and inguinal fat cells is reduced, the number of cells in unit area is significantly increased, the fatty liver sample is relieved, the TMEM26 gene expression in the epididymal fat is significantly increased, and the weight of the obese mouse can be significantly reduced; the expression quantity of the UCP1 gene in brown fat is obviously increased. The traditional Chinese medicine composition adopts medicinal and edible substances as raw materials, is widely applicable to people, is more suitable for prevention and treatment of chronic diseases, is safe and effective, and causes little damage to liver and kidney after long-term use.

The invention discloses a PRP (platelet-rich plasma) stem cell exosome chitosan composition as well as a preparation method and application thereof. The PRP stem cell exosome chitosan composition comprises the following components: activated platelet-rich plasma, stem cell exosome and chitosan. The preparation method of the composite gel comprises the following steps: adding chitosan into a suspension containing activated platelet-rich plasma and stem cell exosome, uniformly mixing, adding a povidone suspending aid, oscillating to form a stable suspension state, adjusting the pH value to 7.5-7.8, mixing with thrombin and a calcium agent, stirring in a dark place, and solidifying to form a gelatinous substance, thereby obtaining the composite gel. The platelet-rich plasma-stem cell exosome-chitosan composite gel is obtained. The composition and the composite gel can promote microvascular endothelial cell regeneration and recover normal vascular endothelial morphology and functions; skin regeneration is promoted; broad-spectrum bacteriostasis and lipid reduction are realized, and local inflammation and immune response are inhibited.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The invention discloses a glycinin compound for preventing hyperlipemia as well as a preparation method and application of the glycinin compound, and belongs to the field of biological medicines. The preparation method comprises the following steps: stirring and mixing resveratrol and a soybean 7S globulin solution at 40-60 DEG C for 1.5-2.5 h, so that resveratrol and soybean 7S globulin are fully combined to obtain a glycinin compound; the mass ratio of the soybean 7S globulin to the resveratrol is (250: 50)-(250: 45). Experimental results show that the glycinin compound disclosed by the invention can inhibit the weight increase of a hyperlipemia rat, remarkably reduce the fat index and the liver index, effectively improve the abnormal change of the blood fat factor level and show an obvious lipid-lowering effect. In-vitro simulated digestion experiments show that the glycinin compound shows peptide fragments with different strength from soybean 7S protein after gastrointestinal digestion, and meanwhile, the glycinin compound improves the in-vitro cholate binding capacity.

According to the subclinical non-obstructive coronary atherosclerosis metaphase plaque progress risk prediction method based on interpretable machine learning provided by the invention, multi-dimensional images and clinical features are integrated, and individualized risk prediction of subclinical non-obstructive coronary atherosclerosis is realized. Quantitative imaging biomarkers are managed for a long time, a key tool is provided for early screening of high-risk individuals, clinical doctors can be helped to judge whether comprehensive strategies such as enhanced lipid lowering, anti-inflammation and lifestyle intervention need to be adopted in time or not, plaque stabilization or fading is maximized, and the clinical effect is improved. And further, the future cardiovascular event risk is reduced. According to the method, a Shapley additive SAHP interpretation technology is introduced, the relative contribution of each prediction feature is quantified, and the interpretability of a machine learning model is improved. According to the method, a webpage tool for calculating the plaque progress probability on line is deployed, and the contribution degree of each feature to the plaque progress prediction result of a specific patient can be displayed more visually.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition suitable for lowering lipid and protecting liver as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw material components: red kidney beans, red yeast rice, Chinese yams, dendrobium nobile, Chinese wolfberry fruits, haws, lily bulbs, coix seeds, white hyacinth beans, fructus perillae, cassia seeds, fresh ginger, rhizoma polygonati, flaxseeds and black fungi. The composition aims at being simple, convenient and low in cost, has the biological activities of resisting oxidation, reducing lipid, protecting the liver, reducing blood sugar and the like, and can regulate lipid metabolism and sugar metabolism of an organism, inhibit oxidative stress reaction, inflammatory reaction and the like.

The invention belongs to the technical field of biological medicines, and relates to application of LSR, LncRNA-LSR-AS1 or targeted siRNA in prevention and / or treatment of hyperlipidemia or related diseases thereof. The invention finds that the overexpression of the LSR gene shows a remarkable lipid-lowering effect in various hyperlipidemia models; the long-chain non-coding RNA (LncRNA-LSR-AS1) is specifically combined with a 3 'UTR (Untranslated Region) region of the LSR mRNA to negatively regulate the expression of the LSR gene; the targeting siRNA designed by aiming at the LncRNA-LSR-AS1 can be used for effectively inhibiting the expression of the LncRNA-LSR-AS1 and relieving the inhibiting effect of the LncRNA-LSR-AS1 on the LSR, so that the expression of the LSR is promoted. Effective intervention on hyperlipidemia can be achieved aiming at the target spots, the effects do not depend on an LDLR channel, and unique value is achieved for familial hypercholesterolemia with the poor PCSK9 inhibitor curative effect.

The invention belongs to the technical field of vegetable protein peptide preparation and functional food, and particularly relates to pea oligopeptide with a lipid-lowering function as well as a preparation method and application of the pea oligopeptide. The amino acid sequences of the pea oligopeptide I, the pea oligopeptide II and the pea oligopeptide III are respectively as shown in SEQ ID NO.1-3. Three pea oligopeptides are obtained through enzymolysis separation in pea protein, and tests prove that the three pea oligopeptides not only have the activity of inhibiting HMG-CoA reductase, but also have the effect of inhibiting the activity of liver cancer cells, and meanwhile, have the effect of inhibiting the activity of HMG-CoA reductase. The traditional Chinese medicine composition has an obvious improvement effect on accumulation of lipid in liver cells and an effect of regulating and controlling expression of lipid metabolism related signal protein, so that the effects of reducing blood fat and preventing and / or improving the non-alcoholic fatty liver disease can be achieved.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The invention provides a lipid-lowering traditional Chinese medicine composition and extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The lipid-lowering traditional Chinese medicine composition is prepared from the following raw materials: rhizoma cyperi and radix gentianae. The invention further provides an extract of the lipid-lowering traditional Chinese medicine composition. The extract is obtained by mixing rhizoma cyperi and radix gentianae and then co-extracting. The composition or the extract can be used for preparing medicines for preventing and / or treating hyperlipemia, and can be used for improving lipid metabolism disorder of liver cells and reducing the content of triglyceride and total cholesterol in the liver cells.

The invention provides a formula of low-sugar low-fat Fu tea ice cream containing partridge tea and a preparation process of the ice cream, and relates to the technical field of food processing. Comprising the following raw material components: 20-40 parts of a partridge tea extracting solution, 15-30 parts of a Fuzhuan tea extracting solution, 8-25 parts of a low-fat milk base material, 5-12 parts of a compound sweetening agent, 3-8 parts of dietary fibers and 2-5 parts of prebiotics. The preparation method has the advantages that the mallotus oblongifolius and the Fuzhuan tea extracting solution are in a specific proportion, the taste is improved through the synergistic effect of tea polyphenol, soft taste and rich flavor levels under the conditions of low sugar (less than or equal to 5%) and low fat (less than or equal to 5%) are achieved, low-temperature short-time sterilization and accurate congelation control are adopted in the process, heat-clearing and dampness-removing components of the mallotus oblongifolius and the bacteriostatic and lipid-lowering activity of golden flower of the Fuzhuan tea are effectively reserved, and the mallotus oblongifolius and the Fuzhuan tea are effectively preserved. The product has double health-care effects, solves the problems of high sugar and high fat, function deficiency and single flavor of the traditional tea-flavored ice cream, meets the requirement of healthy consumption, and has remarkable market value of country revitalizing and Hainan local tourism characteristic food.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a turbidity-dissolving and lipid-lowering composition and a preparation method thereof.The composition comprises 80-130 parts of polygonum cuspidatum, 50-90 parts of fried semen cassiae, 100-140 parts of hawthorn, 50-90 parts of rhizoma alismatis, 10-60 parts of rhizoma atractylodis macrocephalae fried with bran and 50-90 parts of rhizoma wenyujin concisum. The composition disclosed by the invention has the effects of eliminating phlegm, dissolving turbidity, promoting blood circulation to remove blood stasis, invigorating stomach and promoting diuresis, can be used for treating hyperlipidemia, hyperviscosity and arteriosclerotic cardia-cerebrovascular diseases, and has a very good application prospect.

The invention discloses a marine talaromyces brachypodius extract and application thereof, the strain is talaromyces brachypodius QDU-WH004 preserved in China Center for Type Culture Collection on November 24, 2023, the preservation number is CCTCC NO: M 20232329, and the preservation address is Wuhan University Life Science College, Luojia Hill, Wuchang District, Wuchang District, Hubei Province, China. The fermented extract of talaromyces brachypus can effectively inhibit the activity of pancreatic lipase and further inhibit the hydrolysis of dietary triglyceride, so that the effects of reducing fat and losing weight are achieved.

The present invention provides a homogenized pumpkin polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction and purification. The homogenized pumpkin polysaccharide of the present invention contains mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, with the corresponding molar ratios being 0.005:0.004:0.041:0.013:0.545:0.004:0.241:0.147; the relative molecular weight of the homogenized pumpkin polysaccharide is 5.96×10 4 The homogenized pumpkin polysaccharide has significant lipid-lowering and blood sugar-lowering effects. The preparation method has mild process conditions and simple operation. The obtained polysaccharide has high purity and stable structure, and is suitable for industrial-scale production.

The present application provides a composition with lipid-lowering and weight-reducing functions, which has clear components and controllable quality. The composition comprises Pu'er tea extract, wherein the Pu'er tea extract contains 10-90% theabrownine by weight, preferably also contains theophylline, the weight ratio of the theabrownine and theophylline is 10:1-60:1, and contains 0-15% tea polyphenols by weight. The theophylline can be selected from exogenous theophylline or theophylline contained in the Pu'er tea extract. The composition with lipid-lowering and weight-reducing functions of the present application also comprises Poria cocos extract; the weight ratio of the Pu'er tea extract to the Poria cocos extract is 1:3-3:1 based on the weight of theabrownine contained in the Pu'er tea extract. The composition of the present application has the advantages of clear effective components, simple preparation process, controllable quality, and stable lipid-lowering and weight-reducing effects.